Thrombosis Prevention Forum 2010
NATF’s Annual Forum was held on April 10, 2010, The program focused on the improvement of patient care through advancement of thrombosis education. The Proactive Thrombosis Prevention Forum provided a unique educational experience, allowing patients and their families to interact with the professionals who carry out research, provide clinical care, or work on public policy or advocacy issues related to thrombosis.
Thrombosis Prevention Forum:
April 10, 2010, Inn at the Joseph P. Martin Conference Center at the Harvard Medical School, Boston, MA:
LIVE PRESENTATIONS & LECTURE GUIDES
(Click Photo to view Live Presentation)
Charles A. Carter, PharmD, MBA | |
|
Jawed Fareed, PhD | |
|
Jeanine Walenga, PhD | |
Panel Discussion: Drug Safety | |
|
Jessica L. Mega, MD, MPH | |
Jon Corbino | |
|
Charles N. Pozner, MD |
|
|
Brenda Blackburn | |
|
Panel Discussion: Advocacy Issues | |
|
Samuel Z. Goldhaber, MD |
LEARNING OBJECTIVES
The Thrombosis Prevention Forum 2010 is a comprehensive multidisciplinary overview of major issues concerning pulmonary embolism, deep vein thrombosis, sudden cardiac death, acute coronary syndrome, myocardial infarction, and anticoagulant drug safety. The Forum’s objective is to improve patient care through the advancement of thrombosis and cardiovascular education. The approach is multi-disciplinary, targeting patients, advocates, office-based physicians, hospitalists, nurse practitioners, nurses, pharmacists, physician assistants, and hospital administrators. State-of-the-art presentations will incorporate perspectives from clinical research, prevention efforts, educational initiatives, and advocacy. More than 30% of the curriculum is devoted to discussion, questions, and answers. This is a unique educational experience, allowing patients and their families to interact with the healthcare professionals who carry out research, provide clinical care, or work on public policy or advocacy issues related to thrombosis and cardiovascular diseases.Upon completion of this program participants should be able to:
- Discuss the most recent developments concerning the diagnosis and treatment of vascular diseases including:
- deep vein thrombosis
- pulmonary embolism
- thrombophilia
- atrial fibrillation
- importance of completing recommend course of medication
- increased risks to cancer patients
- Understand the patient perspective on thrombosis and cardiovascular disease with the goal of impacting medical treatment in terms of:
- medication compliance
- emotional impact/support
- Summarize United States Congressional bill concerning generic biologics, with regard to concerns for patient safety.
- Review anticoagulants in development in terms of efficacy and safety.
- Discuss the use of antiplatelet drugs for treatment in acute coronary syndrome.
- Understand emergency treatments to prevent and treat sudden cardiac death.
- Recognize issues related to drug safety.
- Recognize issues related to patient advocacy.
TARGET AUDIENCE:
To this end, our program is designed to reach a target audience that includes community physicians, hospital-based physicians, nurses, legislators, government employees who work in the area of health policy and health education, patients, and families of patients.
ACCREDITATION STATEMENTS:
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Utah School of Medicine and the North American Thrombosis Forum (NATF). The University of Utah School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
AMA Credit: The University of Utah School of Medicine designates this educational activity for a maximum of 5.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
The University of Utah College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 5.75 contact hours (.575 CEUs) of credit for pharmacists. ACPE #0068-9999-10-002-L01-P . This program is designed for all pharmacists.
OEO/AA Statement: The University of Utah does not discriminate on the basis of race, color, national origin, sex, disability, age, veteran’s status, or sexual orientation and provides access to all its programs and activities. The following person has been designated to handle inquiries regarding the non-discrimination policies: Manager, OEO/AA,(801) 581-8365, 201 S President’s Circle, RM 135, Salt Lake City, UT 84112.
ADA Statement: The University complies with the Americans with Disabilities Act Amendments Act of 2008 and Section 504 of the Rehabilitation Act by providing qualified individuals with disabilities access to University programs, treatment, services, and activities. A request for accommodation or auxiliary services for: faculty or staff can be made by contacting: Manager, OEO/AA, (801) 581-8365, 201 S President’s Circle, RM 135, Salt Lake City, UT 84112; students and other participants by contacting Director, CDS, (801) 581-5020, 162 Olpin Union Building, Salt Lake City, UT 84112. Reasonable prior notice for accommodation requests is required.
ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
This activity is supported by educational grants from the following companies:
AstraZeneca |
 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
 |
Covidien |
 |
Daiichi Sankyo, Inc. and Lilly USA, LLC |
This activity is supported by an educational grant from Daiichi Sankyo, Inc. and Lilly USA, LLC. |
Eisai |
 |
Ortho-McNeil |
Supported by an educational grant from Ortho-McNeil, Division of Ortho-McNeil Janssen Pharmaceuticals, Inc., administrated by Ortho-McNeil Janssen Scientific Affiars, LCC |
sanofi aventis |
 |
Talecris Biotherapeutics, Center for Science and Education |
 Supported by an eduational grant from Talecris Biotherapeutics, Center for Science and Education |
The Medicines Company |
 |
SUMMIT EXHIBITORS
The following companies have provided support for the Forum through purchase of vendor exhibit space:
Covidien
|
Canyon Pharmceuticals
|
ClotCare
|
Compass HealthCare
|
Medrad Interventional/Possis
|
sanofi-aventis |
Standing Stone, Inc.
|